

Clinical trials of clopidogrel

TrialResults-center www.trialresultscenter.org

1 acute myocardial infarction

Trial	Treatments	Patients	Trials design and methods
clopidogrel vs placebo			
COMMIT , 2005 [NCT00222573] n=22961/22891 follow-up: until discharge or up to 4 wee	clopidogrel 75 mg daily versus placebo	patients admitted to hospital within 24 h of suspected acute MI onset	Parallel groups double-blind
CLARITY-TIMI 28 , 2005 n=NA follow-up: 30 days	clopidogrel (300-mg loading dose, followed by 75 mg once daily) versus placebo	patients, 18 to 75 years of age, within 12 hours after the onset of an ST-elevation myocardial infarction	double blind

More details and results :

- antiplatelets drug for acute myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q390>

References

COMMIT, 2005:

Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005 Nov 5;366:1607-21 [[16271642](#)]

CLARITY-TIMI 28, 2005:

Sabatine MS, Cannon CP, Gibson CM, Lpez-Sendn JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005 Mar 24;352:1179-89 [[15758000](#)]

2 post myocardial infarction

Trial	Treatments	Patients	Trials design and methods
clopidogrel vs aspirin			

continued...

Trial	Treatments	Patients	Trials design and methods
CAPRIE , 1996 n=9599/9586 follow-up: 1.91 y	Clopidogrel (75 mg) 1x/d for a minimum of one year and a maximum of 3 years versus Aspirin (325 mg) 1x/d	patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease	Parallel groups Double blind 16 countries (USA, Canada, Europe, Australia and NZ)

More details and results :

- antiplatelets drug for post myocardial infarction in all type of patient at <http://www.trialresultscenter.org/go-Q277>
- secondary prevention for post myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q449>

References

CAPRIE, 1996:

, A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348:1329-39 [8918275]

2

3 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
clopidogrel vs aspirin			
ASCET [NCT00222261] n=498/503 follow-up:	clopidogrel 75 mg once daily for two years versus Aspirin 160 mg once daily for two years	patients with documented coronary heart disease and treated with aspirin	Parallel groups open
CAPRIE , 1996 n=9599/9586 follow-up: mean 1.91 years	clopidogrel 75 mg once daily versus aspirin 325 mg once daily	patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease	Parallel groups Double blind 16 countries
CAPRIE , 1996 n=3223/3229 follow-up: 1.91 y	Clopidogrel 75 mg versus Aspirine 325 mg	patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease	Parallel groups double blind
clopidogrel vs placebo (on top aspirin)			

continued...

Trial	Treatments	Patients	Trials design and methods
CHARISMA , 2006 [NCT00050817] n=7802/7801 follow-up: median 28 months	clopidogrel (75 mg per day) plus low-dose aspirin (75 to 162 mg per day) versus placebo plus low-dose aspirin	patients with either clinically evident cardiovascular disease or multiple risk factors	Parallel groups Double blind 32 countries

More details and results :

- antiplatelets drug for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q226>
- antiplatelets drug for cardiovascular prevention in secondary prevention in patients with intermittent claudication at <http://www.trialresultscenter.org/go-Q275>
- antiplatelets drug for cardiovascular prevention in secondary prevention in patients with CAD at <http://www.trialresultscenter.org/go-Q276>
- antithrombotics for cardiovascular prevention in secondary prevention at <http://www.trialresultscenter.org/go-Q663>

References

ASCET, :

CAPRIE, 1996:

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996 Nov 16;348:1329-39 [8918275]

CAPRIE, 1996:

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996 Nov 16;348:1329-39 [8918275]

CHARISMA, 2006:

Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Rib Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17 [16531616] 10.1056/NEJMoa060989

4 stable angina

Trial	Treatments	Patients	Trials design and methods
clopidogrel vs aspirin			

continued...

Trial	Treatments	Patients	Trials design and methods
ASCET [NCT00222261] n=498/503 follow-up:	clopidogrel 75 mg once daily for two years versus Aspirin 160 mg once daily for two years	patients with documented coronary heart disease and treated with aspirin	Parallel groups open
CAPRIE , 1996 n=9599/9586 follow-up: mean 1.91 years	clopidogrel 75 mg once daily versus aspirin 325 mg once daily	patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease	Parallel groups Double blind 16 countries

More details and results :

- antithrombotics for stable angina in all type of patient at <http://www.trialresultscenter.org/go-Q33>

References

ASCET, :

CAPRIE, 1996:

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996 Nov 16;348:1329-39 [8918275]

5 heart failure

Trial	Treatments	Patients	Trials design and methods
clopidogrel vs aspirin			
WATCH (clopidogrel vs aspirin) ongoing n=524/523 follow-up:	warfarin (target INR 2.5-3.0) , clopidogrel versus aspirin 162 mg daily	symptomatic heart failure patients in sinus rhythm with ejection fractions 35% taking angiotensin-converting enzyme inhibitors (unless not tolerated) and diuretics	double blind

More details and results :

- antithrombotics for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q73>

References

WATCH (clopidogrel vs aspirin), 0:

ongoing trial

Massie BM, Krol WF, Ammon SE, Armstrong PW, Cleland JG, Collins JF, Ezekowitz M, Jafri SM, O'Connor CM, Packer M, Schulman KA, Teo K, Warren S, The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. *J Card Fail* 2004;10:101-12. [15101020]

Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, Jafri SM, Krol WF, O'Connor CM, Schulman KA, Teo K, Warren SR Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. *Circulation* 2009 Mar 31;119:1616-24 [19289640]

6 atrial fibrillation

Trial	Treatments	Patients	Trials design and methods
aspirin + clopidogrel vs anticoagulant			
ACTIVE W , 2006 [NCT00243178] n=3335/3371 follow-up: 1.28 y (median)	clopidogrel (75 mg per day) plus aspirin (75/100 mg per day) versus oral anticoagulation therapy (target international normalised ratio of 2030)	Patients with atrial fibrillation plus one or more risk factor for stroke	Parallel groups open
aspirin + clopidogrel vs aspirin			
ACTIVE A , 2009 [NCT00249873] n=3772/3782 follow-up: 3.7 y	clopidogrel 75 mg daily + aspirin 75-100 mg daily versus aspirin 75-100 mg daily alone	Patients with AF and at least one risk factor for stroke and who are not candidates for warfarin therapy	Parallel groups double blind

More details and results :

- antithrombotics for atrial fibrillation in primary prevention of thromboembolic events at <http://www.trialresultscenter.org/go-Q57>

References

ACTIVE W, 2006:

Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. *Lancet* 2006 Jun 10;367:1903-12 [16765759]

ACTIVE A, 2009:

Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. *N Engl J Med* 2009 Apr 3;: [19336502]

7 acute coronary syndrome

Trial	Treatments	Patients	Trials design and methods
clopidogrel vs placebo			
COMMIT , 2005 [NCT00222573] n=22961/22891 follow-up: until discharge or up to 4 wee	clopidogrel 75 mg daily versus placebo	patients admitted to hospital within 24 h of suspected acute MI onset	Parallel groups double-blind
CURE (PCI sub study) , 2001 n=1313/1345 follow-up:	pretreatment with clopidogrel +-aspirin 75325 mg) versus placebo (+ aspirin 75325 mg)	patients with non-ST-elevation acute coronary syndrome undergoing PCI	Parallel groups double blind
CLARITY-TIMI 28 , 2005 n=NA follow-up: 30 days	clopidogrel (300-mg loading dose, followed by 75 mg once daily) versus placebo	patients, 18 to 75 years of age, within 12 hours after the onset of an ST-elevation myocardial infarction	double blind
clopidogrel + aspirin vs aspirin			
CURE , 2001 n=6259/6303 follow-up: NA (median <9 months)	clopidogrel 300 mg immediately, followed by 75 mg once daily + aspirin for 3 to 12 months versus aspirin (+placebo)	acute coronary syndromes without ST-segment elevation within 24 hours after the onset of symptoms	Parallel groups double blind 28 countries
clopidogrel high-dose regimen vs clopidogrel standard-dose			
CURRENT OASIS 7 (clopidogrel) , 2010 [NCT00335452] n=12520/12566 follow-up: 30 days	Double-dose clopidogrel versus Standard-dose clopidogrel	ACS patients referred for an invasive strategy (scheduled for percutaneous coronary intervention no more than 72 hours after randomization)	Factorial plan open

More details and results :

- antithrombotics for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q24>
- antiplatelets drug for acute coronary syndrome in ACS (excluding AMI) at <http://www.trialresultscenter.org/go-Q169>
- antiplatelets drug for acute coronary syndrome in patients with scheduled percutaneous coronary intervention at <http://www.trialresultscenter.org/go-Q170>
- antiplatelets drug for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q346>

- antithrombotics for acute coronary syndrome in PCI sub group at <http://www.trialresultscenter.org/go-Q348>
- antiplatelets drug for acute coronary syndrome in STEMI patients at <http://www.trialresultscenter.org/go-Q564>

References

COMMIT, 2005:

Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. *Lancet* 2005 Nov 5;366:1607-21 [[16271642](#)]

CURE (PCI sub study), 2001:

Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. *Lancet* 2001;358:527-33 [[11520521](#)]

CLARITY-TIMI 28, 2005:

Sabatine MS, Cannon CP, Gibson CM, Lpez-Sendn JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. *N Engl J Med* 2005 Mar 24;352:1179-89 [[15758000](#)]

CURE, 2001:

Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med* 2001;345:494-502 [[11519503](#)]

CURRENT OASIS 7 (clopidogrel), 2010:

Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Fox KA, Granger CB, Jolly S, Rupprecht HJ, Widimsky P, Yusuf S Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. *Am Heart J* 2008 Dec;156:1080-1088.e1 [[19033002](#)]

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. *N Engl J Med* 2010 Sep 2;363:930-42 [[20818903](#)] [10.1056/NEJMoa0909475](https://doi.org/10.1056/NEJMoa0909475)

Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP, Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD, Chrolavicius S, Gao P, Fox KA, Yusuf S Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. *Lancet* 2010 Sep 1;: [[20817281](#)] [10.1016/S0140-6736\(10\)61088-4](https://doi.org/10.1016/S0140-6736(10)61088-4)

8 stent

Trial	Treatments	Patients	Trials design and methods
clopidogrel+aspirin vs aspirin			

continued...

Trial	Treatments	Patients	Trials design and methods
REAL-LATE, ZEST-LATE , 2010 [NCT00484926] n=1357/1344 follow-up: 19.2 months	clopidogrel plus aspirin versus aspirin alone	patients who had received drug-eluting stents and had been free of major adverse cardiac or cerebrovascular events and major bleeding for a period of at least 12 months	Parallel groups open South Korea
high-dose clopidogrel vs normal-dose clopidogrel			
GRAVITAS , 2011 [NCT00645918] n=1109/1105 follow-up: 6 months	High-dose clopidogrel (600-mg initial dose, 150 mg daily thereafter) versus regular clopidogrel dose	patients receiving drug-eluting stents with high residual platelet activity (PRU \geq 230) on the regular clopidogrel dose (platelet-function tests with the VerifyNow assay 12 to 24 hours after PCI)	Parallel groups open North America
clopidogrel + aspirin vs ticlopidine + aspirin			
Miller , 2000 n=355/345	Clopidogrel 75 mg qD x4 wks Aspirin 100 mg qD versus Ticlopidine 250 mg BID x4 wks Aspirin 100 mg qD	-	
CLASSICS , 2000 n=345/340	Clopidogrel 300mg x1, 75 mg qD x4 wks Aspirin 325 mg qDyp ‘ versus Ticlopidine 250 mg BID x4 wks Aspirin 325 mg qD	-	
TOPPS , 2001 n=494/522	Clopidogrel 300 mg x1, unsp. Dose x2 wks Aspirin 325 mg qD versus Ticlopidine 500 mg x1, unsp. Dose x2 wks Aspirin 325 mg qD	-	
Piamsomboon , 2001 n=37/31	Clopidogrel 300 mg x1, 75 mg qD x4 wks Aspirin 300 mg BID x4 wks, 300 mg qD versus Ticlopidine 250 mg po BID x4 wks Aspirin 300 mg BID x4 wks, 300 mg qD	-	

More details and results :

- antithrombotics for stent in all type of patients at <http://www.trialresultscenter.org/go-Q151>
- dual antiplatelet therapy for stent in all type of patients at <http://www.trialresultscenter.org/go-Q578>

References

REAL-LATE, ZEST-LATE, 2010:

Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, Han KH, Park SW, Yun SC, Lee SG, Rha SW, Seong IW, Jeong MH, Hur SH, Lee NH, Yoon J, Yang JY, Lee BK, Choi YJ, Chung WS, Lim DS, Cheong SS, Kim KS, Chae JK, Nah DY, Jeon DS, Seung KB, Jang JS, Park HS, Le Duration of dual antiplatelet therapy after implantation of drug-eluting stents. *N Engl J Med* 2010;362:1374-82 [20231231] [10.1056/NEJMoa1001266](#)

GRAVITAS, 2011:

Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillablower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. *JAMA* 2011 Mar 16;305:1097-105 [21406646] [10.1001/jama.2011.290](#)

Miller, 2000:

Miller C, Bttner HJ, Petersen J, Roskamm H A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. *Circulation* 2000;101:590-3 [10673248]

CLASSICS, 2000:

Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). *Circulation* 2000;102:624-9 [10931801]

TOPPS, 2001:

Taniuchi M, Kurz HI, Lasala JM Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. *Circulation* 2001;104:539-43 [11479250]

Piamsomboon, 2001:

Piamsomboon C, Laothavorn P, Chatlaong B, Saguanwong S, Nasawadi C, Tanprasert P, Leelaprute M, Intayakorn U, Amornsak N Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin after coronary stent implantation: 1 and 6-month follow-up. *J Med Assoc Thai* 2001;84:1701-7 [11999816]

9 coronary artery disease

Trial	Treatments	Patients	Trials design and methods
clopidogrel vs aspirin			
ASCET [NCT00222261] n=498/503 follow-up:	clopidogrel 75 mg once daily for two years versus Aspirin 160 mg once daily for two years	patients with documented coronary heart disease and treated with aspirin	Parallel groups open
CAPRIE, 1996 n=9599/9586 follow-up: 1.91 y	Clopidogrel (75 mg) 1x/d for a minimum of one year and a maximum of 3 years versus Aspirin (325 mg) 1x/d	patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease	Parallel groups Double blind 16 countries (USA, Canada, Europe, Australia and NZ)

More details and results :

- death and events prevention for coronary artery disease in all type of patients at <http://www.trialresultscenter.org/go-Q450>

References

ASCET, :

CAPRIE, 1996:

, A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348:1329-39 [8918275]

10 CABG surgery

Trial	Treatments	Patients	Trials design and methods
clopidogrel+aspirin vs aspirin			
CASCADE , 2009 [NCT00228423] n=56/57 follow-up: 1 y	aspirin 162 mg plus clopidogrel 75 mg daily for 1 year versus aspirin 162 mg plus placebo daily	patients after CABG involving at least two saphenous vein grafts	Parallel groups double blind

More details and results :

- antiplatelets drug for CABG surgery in all type of patients at <http://www.trialresultscenter.org/go-Q225>

References

CASCADE, 2009:

Kulik A, Le May M, Wells GA, Mesana TG, Ruel M The clopidogrel after surgery for coronary artery disease (CASCADE) randomized controlled trial: clopidogrel and aspirin versus aspirin alone after coronary bypass surgery [NCT00228423]. Curr Control Trials Cardiovasc Med 2005 Oct 11;6:15 [16219100]

Kulik A, Le May MR, Voisine P, Tardif JC, Delarochelliere R, Naidoo S, Wells GA, Mesana TG, Ruel M Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. Circulation 2010 Dec 21;122:2680-7 [21135365] 10.1161/CIRCULATIONAHA.110.978007

11 peripheral vascular diseases

Trial	Treatments	Patients	Trials design and methods
clopidogrel vs			

continued...

Trial	Treatments	Patients	Trials design and methods
AFFIRM <i>ongoing</i> n=NA	-	-	
clopidogrel vs aspirin			
CAPRIE , 1996 n=3223/3229 follow-up: 1.91 y	Clopidogrel 75 mg versus Aspirine 325 mg	patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease	Parallel groups double blind

More details and results :

- antiplatelets drug for peripheral vascular diseases in all type of patient at <http://www.trialresultscenter.org/go-Q278>
- antithrombotics for peripheral vascular diseases in after revascularisation at <http://www.trialresultscenter.org/go-Q661>

References

AFFIRM, 0:

ongoing trial

CAPRIE, 1996:

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996 Nov 16;348:1329-39 [8918275]

12 percutaneous coronary intervention

Trial	Treatments	Patients	Trials design and methods
clopidogrel+aspirin vs aspirin			
REAL-LATE, ZEST-LATE , 2010 [NCT00484926] n=1357/1344 follow-up: 19.2 months	clopidogrel plus aspirin versus aspirin alone	patients who had received drugeluting stents and had been free of major adverse cardiac or cerebrovascular events and major bleeding for a period of at least 12 months	Parallel groups open South Korea
high-dose clopidogrel vs normal-dose clopidogrel			
GRAVITAS , 2011 [NCT00645918] n=1109/1105 follow-up: 6 months	High-dose clopidogrel (600-mg initial dose, 150 mg daily thereafter) versus regular clopidogrel dose	patients receiving drug-eluting stents with high residual platelet activity (PRU \geq 230) on the regular clopidogrel dose (platelet-function tests with the VerifyNow assay 12 to 24 hours after PCI)	Parallel groups open North America

continued...

Trial	Treatments	Patients	Trials design and methods
clopidogrel + aspirin vs ticlopidine + aspirin			
Miller , 2000 n=355/345	Clopidogrel 75 mg qD x4 wks Aspirin 100 mg qD versus Ticlopidine 250 mg BID x4 wks Aspirin 100 mg qD	-	
CLASSICS , 2000 n=345/340	Clopidogrel 300mg x1, 75 mg qD x4 wks Aspirin 325 mg qDyp ‘ versus Ticlopidine 250 mg BID x4 wks Aspirin 325 mg qD	-	
TOPPS , 2001 n=494/522	Clopidogrel 300 mg x1, unsp. Dose x2 wks Aspirin 325 mg qD versus Ticlopidine 500 mg x1, unsp. Dose x2 wks Aspirin 325 mg qD	-	
Piamsomboon , 2001 n=37/31	Clopidogrel 300 mg x1, 75 mg qD x4 wks Aspirin 300 mg BID x4 wks, 300 mg qD versus Ticlopidine 250 mg po BID x4 wks Aspirin 300 mg BID x4 wks, 300 mg qD	-	

More details and results :

- antithrombotics for percutaneous coronary intervention in PCI with stent placement at <http://www.trialresultscenter.org/go-Q152>
- antiplatelets drug for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q389>
- antithrombotics for percutaneous coronary intervention in patients with high residual platelet activity on clopidogrel at <http://www.trialresultscenter.org/go-Q469>

References

REAL-LATE, ZEST-LATE, 2010:

Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, Han KH, Park SW, Yun SC, Lee SG, Rha SW, Seong IW, Jeong MH, Hur SH, Lee NH, Yoon J, Yang JY, Lee BK, Choi YJ, Chung WS, Lim DS, Cheong SS, Kim KS, Chae JK, Nah DY, Jeon DS, Seung KB, Jang JS, Park HS, Le Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010;362:1374-82 [20231231] 10.1056/NEJMoa1001266

GRAVITAS, 2011:

Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillablower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011 Mar 16;305:1097-105 [21406646] 10.1001/jama.2011.290

Miller, 2000:

Miller C, Bttner HJ, Petersen J, Roskamm H A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. *Circulation* 2000;101:590-3 [[10673248](#)]

CLASSICS, 2000:

Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). *Circulation* 2000;102:624-9 [[10931801](#)]

TOPPS, 2001:

Taniuchi M, Kurz HI, Lasala JM Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. *Circulation* 2001;104:539-43 [[11479250](#)]

Piamsomboon, 2001:

Piamsomboon C, Laothavorn P, Chatlaong B, Saguanwong S, Nasawadi C, Tanprasert P, Leelaprute M, Intayakorn U, Amornsak N Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin after coronary stent implantation: 1 and 6-month follow-up. *J Med Assoc Thai* 2001;84:1701-7 [[11999816](#)]

Entry terms: Plavix, Iscover